BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
about
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsMoving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML.Concordance of randomized and nonrandomized studies was unrelated to translational patterns of two nutrient-disease associations.
P2860
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@ast
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@en
type
label
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@ast
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@en
prefLabel
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@ast
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@en
P2093
P2860
P356
P1433
P1476
BCR-ABL mutation testing to pr ...... with chronic myeloid leukemia
@en
P2093
Issa Dahabreh
Teruhiko Terasawa
Thomas A Trikalinos
P2860
P304
P356
10.1371/CURRENTS.RRN1204
P577
2010-12-07T00:00:00Z